Find Oncology Drugs in Phase II/III Clinical Development

Lead Product(s): Umbralisib,Ublituximab,Bendamustine

Therapeutic Area: Oncology

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 16, 2020

Details:

Drug manufacturer TG Therapeutics, Inc., initiated a rolling application of an NDA for umbralisib seeking rapid FDA approval of the drug for the intended clinical use.

Lead Product(s): Tafasitamab

Therapeutic Area: Oncology

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Incyte

Deal Size: $2,000 million Upfront Cash: $750.0 million

Deal Type: Collaboration January 13, 2020

Details:

MorphoSys and Incyte will co-commercialize tafasitamab in the U.S., while Incyte has exclusive commercialization rights outside of the U.S.